{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000008","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.278899+00:00","generated_at":"2026-06-20T18:00:54.310701+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali outlines 2023 milestones: four late-stage programs, IND for DNL126, OTV expansion","bullets":["Four programs expected in late-stage: DNL310 (MPS II), BIIB122 (Parkinson's), SAR443820 (ALS), DNL343 ALS Phase 2/3","DNL126 (ETV:SGSH) for MPS IIIA: IND submission H1 2023, Phase 1/2 recruitment H2 2023","Oligonucleotide TV platform: five ASO targets selected; two OTV candidates advancing toward clinic","DNL343 (eIF2B activator) ALS: final Phase 1b data mid-2023; Phase 2/3 in HEALEY Platform Trial mid-2023"],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000008","json":"https://secwatch.observer/filing/0001714899-23-000008.json","markdown":"https://secwatch.observer/filing/0001714899-23-000008.md","text":"https://secwatch.observer/filing/0001714899-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000008/0001714899-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000008/dnli-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:00:54.310701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}